Executive summary
US 6,100,061 is a CHO-cell-based platform patent built around (i) long-term stability of recombinant CHO clones in serum- and protein-free culture for at least 40 (and in dependent claims, 50) generations, (ii) a specific clone recovery/adaptation workflow that starts with a serum-containing culture and ends in serum- and protein-free conditions, (iii) defined synthetic “minimum medium” formulations with soybean/yeast peptone plus a defined set of additives, and (iv) expression of specific blood-factor targets including vWF and coagulation factors (notably factor VIII, factor IX, and factor II). The claim set is broad at the “stable CHO recombinant clone in serum/protein-free medium” level, and then narrows through: target product (vWF, factor VIII, factor IX, factor II), clone deposit (ECACC 98012206), and process/formulation specifics (microcarriers, bioreactor scale-up, and the minimum-medium additive package).
A critical read of the landscape is that this patent is “claims-first” about stability and media conditions rather than a single antibody or a single expression construct. That makes it both: (a) an important early blocker for serum-free, scale-relevant CHO platform manufacturing, and (b) vulnerable to design-around and invalidation depending on the prior art record for (1) serum-free CHO stability across passaging generations, (2) serum-to-serum-free adaptation workflows, and (3) serum-free chemically defined media compositions with soybean/yeast peptone and standard small-molecule additives.
What claims does US Patent 6,100,061 cover for serum- and protein-free CHO clones and blood factors?
Core independent claims and what they mean commercially
- Claim 1: A recombinant CHO cell clone that is stable in serum- and protein-free medium for ≥40 generations and expresses a recombinant product.
- Claim 13: A cell culture with >90% stable recombinant CHO cells stable for >50 generations under serum- and protein-free conditions, expressing recombinant product.
- Claim 19: A large-scale production method using an isolated stable original clone (≥40 generations stable in serum/protein-free medium), expanding it in serum/protein-free medium, culturing in a bioreactor, and harvesting from supernatant.
- Claim 33: A serum- and protein-free synthetic medium defined as minimum medium + soybean peptone + glutamine + sodium hydrogencarbonate + ascorbic acid + ethanolamine + sodium selenite.
- Claim 44: A recombinant CHO cell clone cultivated in serum/protein-free for ≥40 generations expressing recombinant product.
Product scope inside the claim family
The claims explicitly call out coagulation-related targets:
- Claim 5: vWF
- Claim 6: Factor VIII
- Claim 7: co-expression factor VIII + vWF
- Claims 8-9: Factor IX and Factor II
Clone scope and “identity hooks”
- Claim 12: The clone is defined by ECACC Deposit No. 98012206 (this is a major enforceability lever because it ties the claim to a specific deposited biological material, limiting ambiguity about what “the clone” is).
- Claim 16: CHO-DHFR- or CHO-K1 backgrounds (broad, but reduces to commonly used CHO lines and those used in classic DHFR amplification workflows).
Media and process scope
Beyond “serum-free,” the claim set locks in specific process elements:
- Serum-to-serum-free re-adaptation workflow (Claim 10, including testing for stable producer cells and recloning under serum-free conditions).
- Microcarrier immobilization (Claims 18 and 23).
- Bioreactor production with supernatant harvest (Claim 19).
- Optional medium variants: yeast extract and soybean extract (Claims 24-25), protease inhibitor (Claim 22), and a detailed additive list (Claim 26).
- A defined synthetic medium package (Claim 33) plus claim 34’s general “minimum medium” definition.
How broad are the claim ranges: “40 vs 50 generations” and “>90% stable cells”?
Featured-snippet style answer: The patent’s strongest gating language is stability thresholds: ≥40 generations (claims 1, 10, 19, 44) and ≥50 generations (claims 2, 13, and corresponding method claims), plus cell-culture population thresholds like >90% stable recombinant cells (claim 13/27).
Why this matters for infringement
- If a competitor’s process uses serum- and protein-free media but uses a shorter adaptation-to-production window or does not demonstrate/maintain the same “generations stable” benchmark, the claim elements can become contested “fact questions” tied to process documentation and stability studies.
- “Generations” is a measurement that can be attacked for definition: how passage number maps to culture generation under scaling and operational changes, and how stability is defined (expression level thresholds, productivity, genetic integrity). The claims do not, on their face, include a quantitative productivity/stability metric in the excerpt you provided, which can shift disputes into claim construction and the written description record.
What patent claims specifically cover vWF and factor VIII co-expression?
Target-specific dependent claim structure
- vWF: Claim 5
- Factor VIII: Claim 6
- Factor VIII + vWF: Claim 7
- Factor IX: Claim 8
- Factor II: Claim 9
Practical enforcement reality
- For litigation or licensing, a competitor expressing vWF or factor VIII in serum-free CHO could still try to avoid the “target” limitation by expressing different blood factors, different polypeptides, or non-orthologous constructs.
- If a competitor co-expresses factor VIII and vWF, claim 7 tightens the net. In coagulation products, co-expression has specific commercial value, making this dependent claim a high-value target for the patentee.
What does the ECACC 98012206 deposit add to enforceability for US 6,100,061?
High-impact hook
- Claim 12: “having ECACC Deposit No. 98012206.”
Why this matters
A deposit number makes the biological identity more determinable. In enforcement, the patentee can argue that infringement hinges on whether the competitor is using the same deposited clone (or an equivalent as defined by the deposit and description). Competitors can still attempt to use different clones derived from different parental lines or constructs, or argue equivalence boundaries.
What formulations are claimed: the serum- and protein-free “minimum medium + soybean peptone” package?
Defined medium claim
- Claim 33 defines a synthetic medium:
- minimum medium
- soybean peptone
- glutamine
- sodium hydrogencarbonate
- ascorbic acid
- ethanolamine
- sodium selenite
Other medium details in dependent claims
- Claim 34: minimum medium includes inorganic salts, amino acids, vitamins, carbohydrate source.
- Claim 21 / 26: variants include a synthetic minimum medium plus optional protease inhibitor and a longer additive list (peptone, L-glutamine, NaHCO3, ascorbic acid, ethanol amine, Na-selenite).
- Claims 24-25: yeast extract and soybean extract variants.
Design-around surface
If a competitor uses a different chemically defined baseline medium, or replaces soybean peptone with alternative nutrient blends (or changes the additive set), they may avoid infringement of medium-specific claims while still practicing around broader “serum- and protein-free stability” claims (or vice versa).
Does US 6,100,061 claim microcarrier and immobilized production systems?
Yes
- Claim 18: cell culture immobilized on a microcarrier.
- Claim 23: method includes cultivating on a microcarrier.
Implication
If a competitor’s manufacturing uses suspension CHO only, they can attempt to limit exposure to microcarrier-specific claims. However, independent claims without microcarrier language may still capture their process if other elements are met.
How strong is the “serum-free stability” concept likely to be against prior art?
Critical assessment of claim novelty logic
The patent’s novelty strategy relies on combining:
- serum- and protein-free culture,
- long-term stability quantified as generations, and
- a specific production-ready clone recovery workflow, plus
- medium composition and additives, and
- coagulation-factor expression targets.
Where prior art pressure typically concentrates in this technology area
For this class of platform claims, invalidity and non-infringement arguments often cluster around:
- Whether serum-free, chemically defined CHO media capable of maintaining stable recombinant producers across many passages was known before the priority date.
- Whether switching from serum-containing to serum-free conditions with re-adaptation and recloning is a routine process known in the art.
- Whether the “minimum medium + peptone + standard additives” formula is essentially an obvious composition set.
- Whether CHO clones were already demonstrated to be stable for many generations in serum-free conditions, using commonly used CHO line backgrounds (DHFR- and CHO-K1).
Without the cited references list and priority details (not provided), a landscape-quality invalidity assessment cannot be completed to the level of enumerating the strongest specific references. The claim architecture indicates that the patentee expects the combination to matter more than any single medium component.
What competitive landscape questions does this patent impact for coagulation biologics?
High-intent buyer/licensor queries
- Does a given biosimilar or follow-on coagulation biologic use CHO stable clones produced in serum-free or chemically defined media?
- Are those processes documented to maintain “≥40 or ≥50 generations stable” producers?
- Do manufacturing scale-up steps include microcarriers and supernatant harvest?
- Are co-expression systems for factor VIII + vWF in scope?
Typical manufacturing facts that become legal elements
- Culture medium used (serum/protein-free and whether it matches the claimed additive package).
- Passage count and how “generations” is defined and documented.
- Clone identity and deposit linkage.
- Expression product and whether it is within the factor/vWF list.
When does US 6,100,061 lose exclusivity, and what does that mean for generic entry risk?
No exclusivity timeline can be stated from the information provided because the key inputs are missing: filing/priority dates, USPTO application history, any terminal disclaimers, and whether this patent is still in force. A correct exclusivity analysis requires those dates and procedural facts, which are not included in your prompt.
What Orange Book or biosimilar relevance applies to US 6,100,061?
The claims cover manufacturing of recombinant proteins in CHO cells rather than a specific small-molecule drug. Orange Book status is therefore product- and reference-drug dependent, but the prompt does not identify: (i) the tied branded drug(s), (ii) the FDA reference product(s), or (iii) any corresponding listed patents. A specific Orange Book mapping cannot be completed from the information provided.
What litigation and licensing outcomes are likely to matter for this patent class?
A complete and actionable litigation landscape requires docket-level information: parties, asserted claims, claim construction, settlements, and PTAB outcomes. None is supplied in the prompt, so a factual litigation analysis cannot be generated.
How to map infringement risk scenarios to the claim elements (operational checklist)
This is a practical element-by-element mapping for infringement scoping based only on the claim language you provided.
Scenario A: Serum-free CHO stable clones for a recombinant factor in supernatant
- Uses CHO clone expressing recombinant product in serum- and protein-free medium.
- Maintains stability for ≥40 (or ≥50) generations.
- Cultures in bioreactor and harvests from supernatant.
- Risk is highest if the recombinant product is vWF, factor VIII, factor IX, factor II, or co-expression of factor VIII + vWF.
Scenario B: Same product but different medium formulation
- If the competitor avoids the specific medium package in claim 33 and dependent claims, they may avoid medium-specific claims.
- But the broader stability-and-clone claims without exact medium composition can still create risk if they meet “serum- and protein-free” stability thresholds.
Scenario C: Different production format (microcarrier vs suspension)
- If the competitor does not use microcarriers, they can reduce exposure to microcarrier-dependent claims (18, 23).
- Independent production claims without microcarrier language remain relevant.
Scenario D: Clone identity differs from deposited ECACC clone
- If a competitor does not use ECACC 98012206 (and does not use a clone that falls within the deposit-defined scope), claim 12 is easier to avoid.
Key takeaways
- US 6,100,061 is a CHO platform patent anchored to measurable stability in serum- and protein-free conditions across defined generation thresholds, with downstream claims covering scale-up and defined synthetic media.
- The enforceability profile is strengthened by (i) stability thresholds that can become evidentiary battlegrounds, and (ii) clone identity through ECACC 98012206.
- The highest commercial exposure sits where recombinant blood-factor products including factor VIII, factor IX, factor II, and vWF, especially factor VIII + vWF co-expression, are manufactured using serum-free, stable CHO clones and operational workflows consistent with the adaptation and production steps.
- Medium-specific claim language (soybean peptone + minimum medium + defined additives) creates design-around paths, but does not automatically eliminate risk because broader “serum- and protein-free stability” claims may still be met.
FAQs
-
What if a manufacturer uses serum-free media but cannot document “≥40 generations” stability?
The claim requires stability for that threshold; infringement can turn on process documentation and stability study evidence tied to the claim elements.
-
Does US 6,100,061 protect only factor VIII products?
No. It also explicitly covers vWF, factor IX, factor II, and combinations such as factor VIII + vWF.
-
Can a competitor avoid the patent by using a different CHO cell line than CHO-K1 or CHO-DHFR−?
Claim 16 limits some embodiments, but other independent claims are not limited to those backgrounds based on the excerpt provided.
-
Are microcarriers a required element for infringement?
No. Microcarriers appear in dependent claims (18, 23). Core independent production claims can be read without that feature.
-
Does claim scope cover only secreted proteins harvested from supernatant?
Claim 19 explicitly includes harvesting from supernatant, but other claims in your list include cell cultures and media definitions. A full interpretation depends on each asserted claim.
References (APA)
No sources were provided in the prompt, and no patent text other than the claim excerpt was included. Therefore, no compliant citation list can be generated from the information given.
